198 related articles for article (PubMed ID: 25744866)
1. Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement.
Rafee S; Elamin YY; Joyce E; Toner M; Flavin R; McDermott R; Sheehy N; Hennessy B; O'Byrne K; Gleeson N; Osman N
Tumori; 2015 Apr; 101(2):e35-9. PubMed ID: 25744866
[TBL] [Abstract][Full Text] [Related]
2. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
Butrynski JE; D'Adamo DR; Hornick JL; Dal Cin P; Antonescu CR; Jhanwar SC; Ladanyi M; Capelletti M; Rodig SJ; Ramaiya N; Kwak EL; Clark JW; Wilner KD; Christensen JG; Jänne PA; Maki RG; Demetri GD; Shapiro GI
N Engl J Med; 2010 Oct; 363(18):1727-33. PubMed ID: 20979472
[TBL] [Abstract][Full Text] [Related]
3. Complete and Repeated Response of a Metastatic ALK-rearranged Inflammatory Myofibroblastic Tumor to Crizotinib in a Teenage Girl.
Gaudichon J; Jeanne-Pasquier C; Deparis M; Veyssière A; Heyndrickx M; Minckes O; Orbach D
J Pediatr Hematol Oncol; 2016 May; 38(4):308-11. PubMed ID: 26808369
[TBL] [Abstract][Full Text] [Related]
4. Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature.
Liu Q; Kan Y; Zhao Y; He H; Kong L
Int J Clin Exp Pathol; 2015; 8(11):15328-32. PubMed ID: 26823889
[TBL] [Abstract][Full Text] [Related]
5. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
[TBL] [Abstract][Full Text] [Related]
6. A novel ALK rearrangement in an inflammatory myofibroblastic tumor in a neonate.
Owusu-Brackett N; Johnson R; Schindel DT; Koduru P; Cope-Yokoyama S
Cancer Genet; 2013; 206(9-10):353-6. PubMed ID: 24290361
[TBL] [Abstract][Full Text] [Related]
7. Management of anaplastic lymphoma kinase positive orbito-conjunctival inflammatory myofibroblastic tumor with crizotinib.
Kiratli H; Uzun S; Varan A; Akyüz C; Orhan D
J AAPOS; 2016 Jun; 20(3):260-3. PubMed ID: 27312965
[TBL] [Abstract][Full Text] [Related]
8. First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer.
Mikes RE; Jordan F; Hutarew G; Studnicka M
Lung Cancer; 2015 Dec; 90(3):614-6. PubMed ID: 26519123
[TBL] [Abstract][Full Text] [Related]
9. Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity.
Ono A; Murakami H; Serizawa M; Wakuda K; Kenmotsu H; Naito T; Taira T; Koh Y; Ohde Y; Nakajima T; Endo M; Takahashi T
Lung Cancer; 2016 Sep; 99():151-4. PubMed ID: 27565932
[TBL] [Abstract][Full Text] [Related]
10. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Costa DB; Shaw AT; Ou SH; Solomon BJ; Riely GJ; Ahn MJ; Zhou C; Shreeve SM; Selaru P; Polli A; Schnell P; Wilner KD; Wiltshire R; Camidge DR; Crinò L
J Clin Oncol; 2015 Jun; 33(17):1881-8. PubMed ID: 25624436
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory Myofibroblastic Tumor Driven by Novel
Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
[TBL] [Abstract][Full Text] [Related]
12. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
Mossé YP; Voss SD; Lim MS; Rolland D; Minard CG; Fox E; Adamson P; Wilner K; Blaney SM; Weigel BJ
J Clin Oncol; 2017 Oct; 35(28):3215-3221. PubMed ID: 28787259
[TBL] [Abstract][Full Text] [Related]
13. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.
Kaneda H; Okamoto I; Nakagawa K
J Thorac Oncol; 2013 Apr; 8(4):e32-3. PubMed ID: 23486271
[No Abstract] [Full Text] [Related]
14. Anaplastic lymphoma kinase positive inflammatory myofibroblastic tumor of the urachus: A rare neoplasm in an unusual location.
Venkatesh K; Madhusudhan HR
Indian J Pathol Microbiol; 2016; 59(1):93-5. PubMed ID: 26960648
[TBL] [Abstract][Full Text] [Related]
15. Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion.
Li Y; Chen X; Qu Y; Fan JM; Li Y; Peng H; Zheng Y; Zhang Y; Zhang HB
J Natl Compr Canc Netw; 2019 Dec; 17(12):1459-1462. PubMed ID: 31805529
[TBL] [Abstract][Full Text] [Related]
16. Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry.
Feng Y; Singh AD; Lanigan C; Tubbs RR; Ma PC
J Thorac Oncol; 2013 Dec; 8(12):e109-11. PubMed ID: 24389446
[No Abstract] [Full Text] [Related]
17. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.
Lovly CM; Gupta A; Lipson D; Otto G; Brennan T; Chung CT; Borinstein SC; Ross JS; Stephens PJ; Miller VA; Coffin CM
Cancer Discov; 2014 Aug; 4(8):889-95. PubMed ID: 24875859
[TBL] [Abstract][Full Text] [Related]
19. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
Cameron L; Solomon B
Drugs; 2015 Jul; 75(10):1059-70. PubMed ID: 26076736
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
Di Maio M; De Marinis F; Hirsch FR; Gridelli C
Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
